Chronic myeloid leukemia (CML) is characterized by an acquired chromosomal translocation known as the Philadelphia chromosome. Simple target inhibition specific for Bcr-Abl can control the disease. Outcomes in CML have drastically changed following the introduction of imatinib, with the majority of patients living a normal lifespan. The abstracts presented at the 2009 American Society of Hematology (ASH) annual meeting suggested optimization of current management with new molecules more potent than imatinib and combination therapy with intention to cure CML. The most clinically relevant abstracts in CML, all of which are published in the November 2009; 114 issue of Blood, are summarized below and identified by abstract number.
ASJC Scopus subject areas